$-0.20 EPS Expected for Vanda Pharmaceuticals Inc. (VNDA)

July 18, 2017 - By Darrin Black

 $ 0.20 EPS Expected for Vanda Pharmaceuticals Inc. (VNDA)
Investors sentiment decreased to 1.29 in 2016 Q4. Its down 1.10, from 2.39 in 2016Q3. It fall, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 46 reduced holdings. 20 funds opened positions while 55 raised stakes. 39.66 million shares or 1.45% less from 40.25 million shares in 2016Q3 were reported.
One Trading L P owns 6,255 shares for 0% of their portfolio. Everpoint Asset Mngmt invested in 0.16% or 525,000 shares. Bogle Investment Ltd Partnership De owns 450,847 shares. One National Association owns 19,071 shares. Castleark Mngmt Ltd reported 0.3% stake. Shell Asset Mngmt has 33,028 shares for 0.01% of their portfolio. Geode Management Ltd Liability holds 0% or 388,583 shares. Ny State Common Retirement Fund owns 148,170 shares for 0% of their portfolio. Cubist Systematic Strategies Ltd Company has invested 0.02% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Smith Asset Mgmt Grp Incorporated Ltd Partnership invested in 0.01% or 18,020 shares. Prelude Mgmt Ltd Liability Com owns 2,800 shares. Parametric Port Assoc Limited Liability has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Weiss Multi holds 50,000 shares. Airain has 14,202 shares. Manufacturers Life Insur The holds 0% or 25,270 shares in its portfolio.

Wall Street await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to release earnings on July, 26. Analysts forecast earnings per share of $-0.20, down exactly $0.16 or 400.00 % from 2014’s $-0.04 EPS. After posting $-0.17 EPS for the previous quarter, Vanda Pharmaceuticals Inc.’s analysts now forecast 17.65 % negative EPS growth. The stock decreased 1.20% or $0.2 during the last trading session, reaching $16.4. About 272,514 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since July 18, 2016 and is uptrending. It has outperformed by 34.90% the S&P500.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 7 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 11 analyst reports since September 2, 2015 according to SRatingsIntel. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. As per Wednesday, September 2, the company rating was maintained by Piper Jaffray. The firm has “Buy” rating by Jefferies given on Thursday, October 6. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Jefferies on Monday, June 26. The rating was initiated by Brean Capital on Wednesday, October 21 with “Buy”. As per Tuesday, June 27, the company rating was initiated by Piper Jaffray. The firm has “Market Outperform” rating by JMP Securities given on Friday, August 26. The rating was initiated by Aegis Capital with “Buy” on Wednesday, November 9.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The company has market cap of $721.96 million. The Firm is focused on the development and commercialization of therapies to address unmet medical needs. It currently has negative earnings. The Company’s product portfolio includes HETLIOZ , Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Prnewswire.com which released: “Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 …” on January 09, 2017, also Prnewswire.com with their article: “Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on …” published on July 17, 2017, Zacks.com published: “Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8% June 21, 2017” on June 21, 2017. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Seekingalpha.com and their article: “Vanda Pharmaceuticals’ (VNDA) CEO Mihael Polymeropoulos on Q3 2016 Results …” published on November 03, 2016 as well as Seekingalpha.com‘s news article titled: “Vanda: Several Catalysts Coming Up” with publication date: June 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.